June 24, 2021
The health ministry’s regenerative medicine panel on June 22 gave the thumbs-up for a PI safety study for JCR Pharmaceuticals’ mesenchymal stem cell therapy Temcell for the treatment of refractory cutaneous ulcers. The study, which will be conducted by Hiroshima...read more